Whether Corcept Therapeutics represents a good investment depends heavily on an individual investor's risk tolerance, growth strategy, and time horizon. Growth-oriented investors frequently highlight its rare status as a profitable commercial-stage biotech firm featuring zero debt, robust cash reserves, double-digit revenue growth, and an innovative pipeline as compelling reasons to buy, while risk-averse investors weigh clinical trial hurdles and regulatory risks.